Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Blood reviews

• Publication date

  2017-08-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.blre.2017.08.004PMID 28802908
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor Immunology

  2018cited by this paper
• Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

  2016cited by this paper
• Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?

  2016cited by this paper
• Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

  2016cited by this paper
• High expression of Bcl-2 predicts poor outcome in diffuse large B-cell lymphoma patients with low international prognostic index receiving R-CHOP chemotherapy

  2016cited by this paper
• Cell Biology: ERADicating Survival with BOK

  2016cited by this paper
• Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

  2016cited by this paper
• Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia.

  2016cited by this paper
• Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibition with ABT-199 Combined With Pharmacologic Loss of MCL1

  2015cited by this paper
• Regulation of Bim in Health and Disease

  2015cited by this paper
• BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?

  2015cited by this paper
• ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells

  2015cited by this paper
• Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

  2015cited by this paper
• A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

  2015cited by this paper
• Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma

  2015cited by this paper
• Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.

  2015cited by this paper
• Targeting TRAIL in the treatment of cancer: new developments

  2015cited by this paper
• Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

  2015cited by this paper
• Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

  2015cited by this paper
• Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.

  2015cited by this paper
• Lessons from gain‐ and loss‐of‐function models of pro‐survival Bcl2 family proteins: implications for targeted therapy

  2015cited by this paper
• Stop competing, start talking!

  2014cited by this paper
• Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

  2014cited by this paper
• Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

  2014cited by this paper
• Histone deacetylase 3 as a novel therapeutic target in multiple myeloma

  2014cited by this paper
• Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells

  2014cited by this paper
• Cooperative Targeting of Bcl-2 Family Proteins By ABT-199 (GDC-0199) and Tyrosine Kinase Inhibitors to Eradicate Blast Crisis CML and CML Stem/Progenitor Cells

  2014cited by this paper
• A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma

  2014cited by this paper
• Synergistic Cytotoxicity of Ibrutinib and the BCL2 Antagonist, ABT-199(GDC-0199) in Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL): Molecular Analysis Reveals Mechanisms of Target Interactions

  2014cited by this paper
• The BCL-2 Inhibitor ABT-199 (GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma

  2014cited by this paper
• miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1.

  2014cited by this paper
• Functional antagonism between pro-apoptotic BIM and anti-apoptotic BCL-XL in MYC-induced lymphomagenesis

  2014cited by this paper
• ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.

  2014cited by this paper
• Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

  2014cited by this paper
• The BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia

  2014cited by this paper
• MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.

  2014cited by this paper
• ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study.

  2014cited by this paper
• Cancer therapeutics: Targeting the apoptotic pathway.

  2014cited by this paper
• A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia.

  2014cited by this paper
• The Carboxyl-terminal Tail of Noxa Protein Regulates the Stability of Noxa and Mcl-1*

  2014cited by this paper
• Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

  2014cited by this paper
• Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.

  2014cited by this paper
• Gossypol induces apoptosis in multiple myeloma cells by inhibition of interleukin-6 signaling and Bcl-2/Mcl-1 pathway

  2014cited by this paper
• A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia

  2014cited by this paper
• Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells.

  2014cited by this paper
• Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

  2014cited by this paper
• Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells

  2014cited by this paper
• A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)

  2014cited by this paper
• Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.

  2013cited by this paper
• Mcl-1 is essential for the survival of plasma cells

  2013cited by this paper
• Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma

  2013cited by this paper
• Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities

  2013cited by this paper
• Bim Polymorphisms: Influence on Function and Response to Treatment in Children with Acute Lymphoblastic Leukemia

  2013cited by this paper
• Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3+ regulatory T cells

  2013cited by this paper
• The chains of death

  2013cited by this paper
• B-cell malignancies in microRNA Eμ-miR-17∼92 transgenic mice

  2013cited by this paper
• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

  2013cited by this paper
• Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.

  2013cited by this paper
• Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.

  2013cited by this paper
• Bax Exists in a Dynamic Equilibrium between the Cytosol and Mitochondria to Control Apoptotic Priming

  2013cited by this paper
• Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease

  2013cited by this paper
• Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance.

  2013cited by this paper
• That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

  2013cited by this paper
• BCL2 mutations in diffuse large B-cell lymphoma

  2012cited by this paper
• Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: prodigiosin vs. obatoclax.

  2012cited by this paper
• BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice

  2012cited by this paper
• Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

  2012cited by this paper
• Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival.

  2012cited by this paper
• A1/Bfl-1 in leukocyte development and cell death

  2012cited by this paper
• Downregulation of BCL2 by AT‐101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner

  2012cited by this paper
• Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• Targeting antiapoptotic A1/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in mice.

  2012cited by this paper
• HDAC inhibitor‐based therapies: Can we interpret the code?

  2012cited by this paper
• A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival.

  2012cited by this paper
• Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs

  2012cited by this paper
• Cytogenetics and molecular cytogenetics in diffuse large B-cell lymphoma (DLBCL).

  2012cited by this paper
• Direct and selective small-molecule activation of proapoptotic BAX.

  2012cited by this paper
• Trials with ‘epigenetic’ drugs: An update

  2012cited by this paper
• Minor cell death defects but reduced tumor latency in mice lacking the BH3-only proteins Bad and Bmf

  2012cited by this paper
• Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.

  2012cited by this paper
• MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia.

  2012cited by this paper
• A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

  2012cited by this paper
• Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model

  2011cited by this paper
• MicroRNA regulation of core apoptosis pathways in cancer.

  2011cited by this paper
• Novel X‐linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL‐mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis

  2011cited by this paper
• Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival.

  2011cited by this paper
• Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.

  2011cited by this paper
• Reduced mast cell and basophil numbers and function in Cpa3-Cre; Mcl-1fl/fl mice.

  2011cited by this paper
• The BCL-2 family reunion.

  2010cited by this paper
• Individual and overlapping roles of BH3-only proteins Bim and Bad in apoptosis of lymphocytes and platelets and in suppression of thymic lymphoma development

  2010cited by this paper
• PUMA-mediated tumor suppression: A tale of two stories

  2010cited by this paper
• Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development

  2010cited by this paper
• A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

  2010cited by this paper
• Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia.

  2010cited by this paper
• Systems biology of apoptosis signaling networks.

  2010cited by this paper
• A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy

  2010cited by this paper
• The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.

  2010cited by this paper
• The landscape of somatic copy-number alteration across human cancers

  2010cited by this paper

• Computational identification of Mcl-1 inhibitors through molecular docking, ADMET, QSAR, and molecular dynamics simulations: anti-leukemic phytocompounds

  2026cites this paper
• Regulation of PEST-containing nuclear proteins in cancer cells: implications for cancer biology and therapy

  2025cites this paper
• miR-153 Overexpression and BCL2 Targeting Induce Apoptosis and Autophagy in HepG2 Cells

  2025cites this paper
• Venetoclax plus azacitidine in relapsed or refractory T-cell acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 trial.

  2025cites this paper
• Identification of Plasma Protein Biomarkers and Drug Targets for Hematologic Malignancies by Proteome-wide Mendelian Randomization

  2025cites this paper
• Oral Combined Probiotics Clostridium butyricum and Akkermansia muciniphila Inhibits the Progression of 4T1 Breast Cancer by Activating Bcl‐2/Bax Pathway

  2025cites this paper
• Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center

  2024cites this paper
• In vitro and in vivo evaluation of novel chromeno[2,3-d]pyrimidinones as therapeutic agents for triple negative breast cancer.

  2024cites this paper
• A promising future of metal‐N‐heterocyclic carbene complexes in medicinal chemistry: The emerging bioorganometallic antitumor agents

  2024cites this paper
• Cytotoxic Effects of the Combination of Pam3CSK4 with Carfilzomib, Ixazomib, and Venetoclax in Human Multiple Myeloma Cells

  2024cites this paper
• Protective Role of Vitamin D Receptor in Cerebral Ischemia/Reperfusion Injury In Vitro and In Vivo Model.

  2024cites this paper
• Design and green synthesis of asymmetric 3,4,5-trimethoxyphenyl-inspired 1,5-diaryl-1,4-pentadien-3-ones as potent anti-gastric cancer agents through ROS and JNK-triggered apoptosis

  2024cites this paper
• Protective effects of dietary protein against nitrite stress in grass carp (Ctenopharyngodon idella): A new perspective

  2024cites this paper
• Inhibitory effect of Curcumin on a cervical cancer cell line via the RAS/RAF signaling pathway.

  2024cites this paper
• Anticancer Effects in HT-29 Cells and Anti-Inflammatory Effects on Mouse Splenocytes of Broccoli Cultivated with Deep Sea Water Minerals in Organic Farming

  2023cites this paper
• Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies

  2023cites this paper
• Exploring the Pharmacological Versatility of Ficus Carica: Modulating Classical Immunometabolism and Beyond.

  2023cites this paper
• Increased Anticancer Activity of Organic Kimchi with Starters Demonstrated in HT-29 Cancer Cells

  2023cites this paper
• Insights into the Origin and Therapeutic Implications of Benzopyran and Its Derivatives

  2023cites this paper
• Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth

  2023cites this paper
• The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients

  2023influential citation
• Protective effect of ZYMT, a traditional Chinese patent medicine in a mouse model of retinitis pigmentosa.

  2023cites this paper
• An Enriched Environment Promotes Motor Function through Neuroprotection after Cerebral Ischemia

  2023cites this paper
• Chloroform Fraction of Drymaria Cordata Linn (CFDC) Suppresses Estradiol Benzoate-induced Endometrial Hyperplasia.

  2023cites this paper
• Aging, oxidative stress and degenerative diseases: mechanisms, complications and emerging therapeutic strategies

  2023cites this paper
• Phytochemical profiling and cytotoxic potential of Arnebia nobilis root extracts against hepatocellular carcinoma using in-vitro and in-silico approaches

  2023cites this paper
• Dihydroaustrasulfone alcohol induces apoptosis in nasopharyngeal cancer cells by inducing reactive oxygen species-dependent inactivation of the PI3K/AKT pathway

  2023cites this paper
• A diagnostic and prognostic value of blood-based circulating long non-coding RNAs in Thyroid, Pancreatic and Ovarian Cancer.

  2022cites this paper
• Extracts of Bauhinia Championii Alleviate Acute Neuronal Injury After Ischemic Reperfusion by Improving Endoplasmic Reticulum Stress-Mediated Neuronal Apoptosis

  2022cites this paper
• The Expression Pattern of Bcl-2 and Bax in the Tumor and Stromal Cells in Colorectal Carcinoma

  2022cites this paper
• Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐xL Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches

  2022cites this paper
• Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells.

  2022cites this paper
• Polyphenols: Chemoprevention and therapeutic potentials in hematological malignancies

  2022cites this paper
• Annona muricata Linn Stem Bark Protects against Uterine Proliferative Disorder Induced by Estradiol Benzoate in Female Rat

  2022cites this paper
• Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells

  2021cites this paper
• Progesterone induces apoptosis by activation of caspase-8 and calcitriol via activation of caspase-9 pathways in ovarian and endometrial cancer cells in vitro

  2021cites this paper
• Novel Copper(II) Complex with a 4-Acylpyrazolone Derivative and Coligand Induce Apoptosis in Liver Cancer Cells.

  2021cites this paper
• The structure elucidation of novel arabinogalactan LRP1-S2 against pancreatic cancer cells growth in vitro and in vivo.

  2021cites this paper
• Protective effect of propofol via the regulation of ovarian granulosa cell proliferation and apoptosis

  2021cites this paper
• Ferruginol-induced apoptosis in Human Colon Cancer Cells (HCT-116) through the mitochondria-mediated apoptotic pathway

  2021cites this paper
• Discovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton.

  2021cites this paper
• Anti-proliferative and apoptotic effect of tetrahydrobenzo[h]quinoline on MCF-7 human breast cancer cell

  2021cites this paper
• Current Biomarkers of Apoptosis Process in Chronically Inflamed Nasal Sinus Epithelium: Representatives of BAX, Bcl-2 and miRNA Group

  2021cites this paper
• Artificial intelligence-based identification of octenidine as a Bcl-xL inhibitor.

  2021cites this paper
• Dual-targeted cationic liposomes modified with hyaluronic acid and folic acid deliver siRNA Bcl-2 in the treatment of cervical cancer

  2020cites this paper
• Polyphyllin A suppresses growth and promotes apoptosis by partially decreasing CIP2A expression in lymphoma cell lines

  2020cites this paper
• Circular RNA hsa_circ_0000848 Promotes Trophoblast Cell Migration and Invasion and Inhibits Cell Apoptosis by Sponging hsa-miR-6768-5p

  2020cites this paper
• Molecular approaches for targeted drug delivery towards cancer: A concise review with respect to nanotechnology

  2020cites this paper
• Integrating Ligand and Target-Driven Based Virtual Screening Approaches With in vitro Human Cell Line Models and Time-Resolved Fluorescence Resonance Energy Transfer Assay to Identify Novel Hit Compounds Against BCL-2

  2020cites this paper
• Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer

  2020cites this paper
• Surface functionalization of pegylated gold nanoparticles with antioxidants suppresses nanoparticle-induced oxidative stress and neurotoxicity.

  2020cites this paper
• Anti-apoptotic BCL-2 family proteins confer resistance to calicheamicin-based antibody-drug conjugate therapy of acute leukemia

  2020cites this paper
• Inhibitor of protein kinases 1-(4-chlorobenzyl)-3-chloro-4-(3-trifluoromethylphenylamino)-1Н-pyrrole-2,5-dione induces DNA damage and apoptosis in human colon carcinoma cells

  2020cites this paper
• A mechanistic review: potential chronic disease-preventive properties of sorghum.

  2020cites this paper
• Radix Tetrastigma flavonoids inhibit the migration and promote the apoptosis of A549 cells both in vitro and in vivo

  2020cites this paper
• The Tumor Suppressor Role of the Ras Association Domain Family 10.

  2020cites this paper
• Unravelling the anticancer potential of functionalized chromeno[2,3-b]pyridines for breast cancer treatment.

  2020cites this paper
• Cucurbitacin B induces inhibitory effects via the CIP2A/PP2A/C-KIT signaling axis in t(8;21) acute myeloid leukemia.

  2019cites this paper
• Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy

  2019cites this paper
• Co-delivery of curcumin and Bcl-2 siRNA by PAMAM dendrimers for enhancement of the therapeutic efficacy in HeLa cancer cells.

  2019cites this paper
• Garlic-derived bioactive compound S-allylcysteine inhibits cancer progression through diverse molecular mechanisms.

  2019cites this paper
• The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL)

  2019cites this paper
• Magnolol inhibits growth and induces apoptosis in esophagus cancer KYSE-150 cell lines via the MAP kinase pathway.

  2019cites this paper
• Taking a holistic view of PEST‐containing nuclear protein (PCNP) in cancer biology

  2019cites this paper
• Varacin-1, a novel analog of varacin C, induces p53-independent apoptosis in cancer cells through ROS-mediated reduction of XIAP

  2018cites this paper
• Computational approach toward targeting the interaction of porphyrin derivatives with Bcl-2

  2018cites this paper
• Hormonally induced defects of DNA damage repair genes: an oncogenic driver of prostate cancer

  2018cites this paper
• A phosphorescent cyclometalated iridium(III) complex as mitochondria-targeted theranostic anticancer agent

  2018cites this paper
• Protective Effects of Costunolide Against D-Galactosamine and Lipopolysaccharide-Induced Acute Liver Injury in Mice

  2018cites this paper
• STAT3 and apoptosis challenges in cancer.

  2018cites this paper
• Protein phosphatase 2A mediates JS‐K‐induced apoptosis by affecting Bcl‐2 family proteins in human hepatocellular carcinoma HepG2 cells

  2018cites this paper
• Identification and validation of NOLC1 as a potential target for enhancing sensitivity in multidrug resistant non-small cell lung cancer cells

  2018cites this paper
• Polyphyllin I Inhibits Proliferation and Induces Apoptosis by Downregulating AML1‐ETO and Suppressing C‐KIT/Akt Signaling in t(8;21) Acute Myeloid Leukemia

  2018cites this paper
• Mutant KLF1 in Adult Anemic Nan Mice Leads to Profound Transcriptome Changes and Disordered Erythropoiesis

  2018cites this paper
• Benzyl isothiocyanate (BITC) triggers mitochondria-mediated apoptotic machinery in human cisplatin-resistant oral cancer CAR cells

  2018cites this paper
• Exploitation of new chalcones and 4H-chromenes as agents for cancer treatment.

  2018cites this paper
• Dishevelled1-3 contribute to multidrug resistance in colorectal cancer via activating Wnt/β-catenin signaling

  2017cites this paper
• on a cervical cancer cell line via the RAS/RAF

  year unknowncites this paper